Quoin Pharma to begin clinical study in New Zealand to evaluate QRX003 to treat paediatric patient with peeling skin syndrome
Overview
Quoin Pharmaceuticals Ltd., a clinical stage, specialty pharmaceutical company, announced the planned initiation of an investigator-led clinical study in New Zealand to evaluate the safety and efficacy of QRX003 in a paediatric patient with peeling skin syndrome (PSS).
About QRX003
- QRX003 is Quoin’s most advanced pipeline product and is currently being evaluated in two late stage clinical trials in the United States as a potential treatment for Netherton syndrome (NS).
- Both studies are being conducted under an open Investigational New Drug (IND) application with the Food and Drug Administration (FDA).
Words from CEO: Quoin Pharmaceuticals
- We are excited to expand QRX003’s development into this second indication, peeling skin syndrome, where it is believed the mechanism of action of our product could also provide a benefit for this devastating disease. Given the overlapping nature of how PSS presents, patients with the disease are known to have been previously misdiagnosed as having NS.”
- •Currently there are no clinical studies listed for peeling skin syndrome on clinicaltrials.gov as actively recruiting and dosing subjects and there is no approved treatment or cure, presenting a further opportunity for Quoin to achieve the first regulatory approval for another rare genetic disease,” stated Michael Myers, CEO, Quoin Pharmaceuticals.
- •The planned initiation of this study represents the execution of a key pillar of Quoin’s strategy to expand the clinical testing of QRX003 into other rare and orphan disease indications and we are actively assessing additional opportunities beyond this one.”
QRX003 - QRX003 is a unique “whole body, whole life” topical lotion that targets the vicious circle of skin inflammation and barrier disruption.
Quoin is conducting two ongoing clinical trials evaluating QRX003 for the treatment of Netherton syndrome.
About PSS
- Generalized inflammatory peeling skin syndrome (PSS) is a rare autosomal recessive genodermatosis caused by loss-of-function disease-causing variants of the corneodesmosin gene (CDSN), resulting in excessive shedding of the superficial layers of the epidermis.
- Patients generally suffer from a variety of conditions including severe pain and chronic pruritis (itch).
- There is currently no approved treatment for PSS, and patients manage symptoms using over-the-counter emollients.
QRX003 lotions
- QRX003 is a topical lotion, formulated with a proprietary delivery technology, and contains a broad- spectrum serine protease inhibitor, whose mechanism of action is intended to perform the function of a specific protein, called LEKTI.
- The absence of LEKTI in Netherton patients leads to excessive skin shedding resulting in a highly porous and compromised skin barrier.
- QRX003 is designed to lead to a more normalized skin shedding process and the formation of a stronger and more effective skin barrier.
Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is an emerging specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases.
